BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Lupin signs agreement with Gan & Lee Pharma for novel GLP-1 receptor agonist

December 29, 2025 | News

Lupin will have exclusive rights to commercialise and distribute Bofanglutide in India



Indian pharma major Lupin Limited has entered into an exclusive License, Supply and Distribution agreement with Gan & Lee Pharmaceuticals, headquartered in China, for a novel fortnightly GLP-1 receptor agonist, Bofanglutide.

The agreement strengthens Lupin's diabetes portfolio and accelerates its presence in the obesity segment. Bofanglutide injection is a fortnightly (once in two weeks) GLP-1 receptor agonist developed by Gan & Lee, intended for treating adults with type 2 diabetes and aiding weight management in overweight or obese individuals.

As a potential first-in-class global fortnightly GLP-1 agonist, clinical data demonstrate that the weight loss results of Bofanglutide are comparable to or better than those of existing GLP-1 alternatives while offering the convenience of once in two weeks versus once a week for other injectable alternatives, and maintaining safety and tolerability consistent with the GLP-1 class. It effectively reduces both blood glucose levels and body weight.

Obesity is anticipated to develop into a significant health crisis in India, with approximately 174 million adults classified as overweight and around 50 million as obese. Diabetes is already considered an epidemic, with approximately 90 million adults affected by the condition. Under the terms of the agreement, Lupin will have exclusive rights to commercialise and distribute Bofanglutide in India.